Loading
ADC Therapeutics S.A. operates as a commercial-stage biotechnology company, focused on developing antibody-drug conjugates (ADCs) for the treatment of hematological malignancies and solid tumors. Its flagship product, ZYNLONTA, is presently being evaluated in multiple clinical trials: a Phase II study for relapsed or refractory diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma; a Phase III trial assessing its combination with rituximab for second-line, transplant-ineligible patients with relapsed or refractory DLBCL; and a Phase I trial for relapsed or refractory non-Hodgkin lymphoma (NHL). The company's pipeline also includes camidanlumab tesirine, another ADC, which has completed Phase I development for relapsed or refractory NHL. It is additionally progressing through Phase II for relapsed or refractory Hodgkin lymphoma and Phase Ib for selected advanced solid tumors. Furthermore, ADC Therapeutics is advancing ADCT-602, currently in Phase Ia for acute lymphoblastic leukemia, alongside ADCT-601 and ADCT-901, both of which are in Phase Ia for various solid tumors. Its preclinical portfolio features ADCT-701 and ADCT-901, both aimed at solid tumors. The company maintains strategic collaboration and license agreements with entities such as Genmab A/S, Bergenbio AS, Synaffix B.V., Mitsubishi Tanabe Pharma Corporation, Overland Pharmaceuticals, and MedImmune Limited. Founded in 2011, ADC Therapeutics S.A. has its headquarters located in Epalinges, Switzerland.
Previous close
$1.30
−$0.06 · -4.41%
After-hours
$1.30
$0.00 · 0.00%
Sep 8, 5:36 PM ET
Regular session · ET · Market data may be delayed.
ADC Therapeutics S.A. operates as a commercial-stage biotechnology company, focused on developing antibody-drug conjugates (ADCs) for the treatment of hematological malignancies and solid tumors. Its flagship product, ZYNLONTA, is presently being evaluated in multiple clinical trials: a Phase II study for relapsed or refractory diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma; a Phase III trial assessing its combination with rituximab for second-line, transplant-ineligible patients with relapsed or refractory DLBCL; and a Phase I trial for relapsed or refractory non-Hodgkin lymphoma (NHL). The company's pipeline also includes camidanlumab tesirine, another ADC, which has completed Phase I development for relapsed or refractory NHL. It is additionally progressing through Phase II for relapsed or refractory Hodgkin lymphoma and Phase Ib for selected advanced solid tumors. Furthermore, ADC Therapeutics is advancing ADCT-602, currently in Phase Ia for acute lymphoblastic leukemia, alongside ADCT-601 and ADCT-901, both of which are in Phase Ia for various solid tumors. Its preclinical portfolio features ADCT-701 and ADCT-901, both aimed at solid tumors. The company maintains strategic collaboration and license agreements with entities such as Genmab A/S, Bergenbio AS, Synaffix B.V., Mitsubishi Tanabe Pharma Corporation, Overland Pharmaceuticals, and MedImmune Limited. Founded in 2011, ADC Therapeutics S.A. has its headquarters located in Epalinges, Switzerland.
Day range
Current $1.30
52-week range
Current $1.30
Regular session · ET · Market data may be delayed.
GoAI Score
Hold
Valuation
75
Undervalued
Sentiment
67
Bullish
Risk
76
High Risk
Momentum
19
Strong Down
Full GoAI research
Thesis, catalysts, evidence, and risk analysis.
ADC Therapeutics S.A. operates as a commercial-stage biotechnology company, focused on developing antibody-drug conjugates (ADCs) for the treatment of hematological malignancies and solid tumors. Its flagship product, ZYNLONTA, is presently being evaluated in multiple clinical trials: a Phase II study for relapsed or refractory diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma; a Phase III trial assessing its combination with rituximab for second-line, transplant-ineligible patients with relapsed or refractory DLBCL; and a Phase I trial for relapsed or refractory non-Hodgkin lymphoma (NHL). The company's pipeline also includes camidanlumab tesirine, another ADC, which has completed Phase I development for relapsed or refractory NHL. It is additionally progressing through Phase II for relapsed or refractory Hodgkin lymphoma and Phase Ib for selected advanced solid tumors. Furthermore, ADC Therapeutics is advancing ADCT-602, currently in Phase Ia for acute lymphoblastic leukemia, alongside ADCT-601 and ADCT-901, both of which are in Phase Ia for various solid tumors. Its preclinical portfolio features ADCT-701 and ADCT-901, both aimed at solid tumors. The company maintains strategic collaboration and license agreements with entities such as Genmab A/S, Bergenbio AS, Synaffix B.V., Mitsubishi Tanabe Pharma Corporation, Overland Pharmaceuticals, and MedImmune Limited. Founded in 2011, ADC Therapeutics S.A. has its headquarters located in Epalinges, Switzerland.
Day range
Current $1.30
52-week range
Current $1.30
Recent quarterly results
Recent quarterly results
Third-party consensus; not a GoAI recommendation.
Funds reporting this stock among their holdings, ordered by reported position size.
iShares Russell 2000 ETFIWM3.56M0.00%80.51B USD0.19%$294.67-0.45%
iShares Russell 2000 Value ETFIWN941.33K0.01%14.61B USD0.24%$222.76-0.83%
iShares Biotechnology ETFIBB935.67K0.01%10.73B USD0.44%$207.33-2.17%
Vanguard Russell 2000 ETFVTWO634.55K0.00%17.4B USD0.06%$119.14-0.40%
iShares Micro-Cap ETFIWC475.72K0.03%1.49B USD0.60%$195.17-0.74%
iShares Russell 2000 Growth ETFIWO266.5K0.00%14.7B USD0.24%$377.11-0.11%
State Street SPDR S&P International Small Cap ETFGWX107.37K0.01%943.98M USD0.40%$46.78-0.34%
Vanguard Russell 2000 Value ETFVTWV81.26K0.01%1.4B USD0.06%$196.48-0.84%iShares Russell 2000 ETFIWMiShares Russell 2000 Value ETFIWNiShares Biotechnology ETFIBBVanguard Russell 2000 ETFVTWOiShares Micro-Cap ETFIWCiShares Russell 2000 Growth ETFIWOState Street SPDR S&P International Small Cap ETFGWXVanguard Russell 2000 Value ETFVTWVAI-generated and delayed market data for informational and educational purposes only. Not investment advice.
